AU780747B2 - Process for preparing crystalline form I of cabergoline - Google Patents

Process for preparing crystalline form I of cabergoline Download PDF

Info

Publication number
AU780747B2
AU780747B2 AU62110/01A AU6211001A AU780747B2 AU 780747 B2 AU780747 B2 AU 780747B2 AU 62110/01 A AU62110/01 A AU 62110/01A AU 6211001 A AU6211001 A AU 6211001A AU 780747 B2 AU780747 B2 AU 780747B2
Authority
AU
Australia
Prior art keywords
cabergoline
toluene
diethyl ether
solvate
ether mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62110/01A
Other languages
English (en)
Other versions
AU6211001A (en
Inventor
Stefania Magenes
Gianfranco Pallanza
Giuliano Ramella
Attilio Tomasi
Mario Ungari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU780747(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of AU6211001A publication Critical patent/AU6211001A/en
Application granted granted Critical
Publication of AU780747B2 publication Critical patent/AU780747B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU62110/01A 2000-03-24 2001-03-19 Process for preparing crystalline form I of cabergoline Ceased AU780747B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007308 2000-03-24
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005203071A Division AU2005203071B2 (en) 2000-03-24 2005-07-14 Process for preparing crystalline form I of cabergoline

Publications (2)

Publication Number Publication Date
AU6211001A AU6211001A (en) 2001-10-03
AU780747B2 true AU780747B2 (en) 2005-04-14

Family

ID=9888433

Family Applications (2)

Application Number Title Priority Date Filing Date
AU62110/01A Ceased AU780747B2 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form I of cabergoline
AU2005203071A Ceased AU2005203071B2 (en) 2000-03-24 2005-07-14 Process for preparing crystalline form I of cabergoline

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005203071A Ceased AU2005203071B2 (en) 2000-03-24 2005-07-14 Process for preparing crystalline form I of cabergoline

Country Status (31)

Country Link
US (2) US6727363B2 (cg-RX-API-DMAC7.html)
EP (1) EP1272489B1 (cg-RX-API-DMAC7.html)
JP (1) JP4184666B2 (cg-RX-API-DMAC7.html)
KR (1) KR100827558B1 (cg-RX-API-DMAC7.html)
CN (1) CN1188412C (cg-RX-API-DMAC7.html)
AR (1) AR032449A1 (cg-RX-API-DMAC7.html)
AT (1) ATE250601T1 (cg-RX-API-DMAC7.html)
AU (2) AU780747B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109507A (cg-RX-API-DMAC7.html)
CA (1) CA2402836A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20023176A3 (cg-RX-API-DMAC7.html)
DE (1) DE60100858T2 (cg-RX-API-DMAC7.html)
DK (1) DK1272489T3 (cg-RX-API-DMAC7.html)
EA (1) EA005928B1 (cg-RX-API-DMAC7.html)
EE (1) EE05088B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208602T3 (cg-RX-API-DMAC7.html)
GB (1) GB0007308D0 (cg-RX-API-DMAC7.html)
HK (1) HK1052348B (cg-RX-API-DMAC7.html)
HU (1) HUP0300591A3 (cg-RX-API-DMAC7.html)
IL (2) IL150985A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02009283A (cg-RX-API-DMAC7.html)
MY (1) MY134189A (cg-RX-API-DMAC7.html)
NO (1) NO20024321L (cg-RX-API-DMAC7.html)
NZ (1) NZ521316A (cg-RX-API-DMAC7.html)
PE (1) PE20011140A1 (cg-RX-API-DMAC7.html)
PL (1) PL358253A1 (cg-RX-API-DMAC7.html)
PT (1) PT1272489E (cg-RX-API-DMAC7.html)
SI (1) SI1272489T1 (cg-RX-API-DMAC7.html)
SK (1) SK13582002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001070740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200206045B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
RS81804A (sr) * 2002-03-15 2006-10-27 Pharmacia Corporation Postupak za dobijanje kristalnog oblika kabergolina
WO2003078392A2 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
AU2004238833A1 (en) * 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
JPH08502759A (ja) 1993-08-18 1996-03-26 アルコン ラボラトリーズ,インコーポレイテッド 緑内障治療用のエルゴリン誘導体の使用
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
PL343593A1 (en) 1998-03-27 2001-08-27 Upjohn Co Use of cabergoline in the treatment of restless legs syndrome
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUR J MED CHEM 1989 VOL. 24 PP 421-426 *

Also Published As

Publication number Publication date
US20040092744A1 (en) 2004-05-13
AU2005203071A1 (en) 2005-08-11
DK1272489T3 (da) 2003-12-15
NZ521316A (en) 2004-05-28
MXPA02009283A (es) 2003-03-12
SK13582002A3 (sk) 2003-04-01
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
AU6211001A (en) 2001-10-03
EA200201016A1 (ru) 2003-02-27
EA005928B1 (ru) 2005-08-25
MY134189A (en) 2007-11-30
HK1052348B (zh) 2005-09-16
ZA200206045B (en) 2003-07-29
AR032449A1 (es) 2003-11-12
GB0007308D0 (en) 2000-05-17
IL150985A0 (en) 2003-02-12
PT1272489E (pt) 2004-02-27
JP4184666B2 (ja) 2008-11-19
KR100827558B1 (ko) 2008-05-07
EE05088B1 (et) 2008-10-15
US6953854B2 (en) 2005-10-11
NO20024321D0 (no) 2002-09-10
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DE60100858D1 (de) 2003-10-30
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
HK1052348A1 (en) 2003-09-11
PE20011140A1 (es) 2001-11-01
WO2001070740A1 (en) 2001-09-27
ATE250601T1 (de) 2003-10-15
CN1188412C (zh) 2005-02-09
PL358253A1 (en) 2004-08-09
HUP0300591A3 (en) 2009-01-28
NO20024321L (no) 2002-09-10
EE200200545A (et) 2004-04-15
US6727363B2 (en) 2004-04-27
DE60100858T2 (de) 2004-07-29
EP1272489A1 (en) 2003-01-08
US20030149067A1 (en) 2003-08-07
EP1272489B1 (en) 2003-09-24
HUP0300591A2 (hu) 2003-07-28
JP2003528100A (ja) 2003-09-24
SI1272489T1 (en) 2004-02-29
IL150985A (en) 2007-03-08
KR20020081587A (ko) 2002-10-28

Similar Documents

Publication Publication Date Title
AU2005203071B2 (en) Process for preparing crystalline form I of cabergoline
US6673806B2 (en) Crystalline form II cabergoline
US6680327B2 (en) Crystalline form VII of cabergoline
US20040209910A1 (en) Forms of cabergoline

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANTS TO READ: PHARMACIA ITALIA S.P.A. AS SOLE APPLICANT